Target Name: SNORD115-29
NCBI ID: G100033803
Review Report on SNORD115-29 Target / Biomarker Content of Review Report on SNORD115-29 Target / Biomarker
Other Name(s): small nucleolar RNA, C/D box 115-29 | HBII-52-29 | Small nucleolar RNA, C/D box 115-29

Understanding SNORD115-29: A Promising Biomarker for Disease

In recent years, significant advancements have been made in the field of molecular biology, leading to better insights into various diseases, their underlying mechanisms, and potential therapeutic targets. Among the numerous molecules and biomarkers discovered, SNORD115-29 has emerged as a particularly intriguing candidate. This article aims to provide a comprehensive overview of SNORD115-29, its role as a potential disease drug target or biomarker, and its implications for future research and clinical applications.

The Discovery of SNORD115-29
SNORD115-29 represents a subclass of small nucleolar RNAs (snoRNAs) that are transcribed from specific regions of the human genome. SnoRNAs were initially thought to primarily function in ribosomal RNA (rRNA) processing and modification. However, recent studies have shed light on their involvement in various cellular processes, including gene regulation, alternative splicing, and post-transcriptional modifications.

The identification of SNORD115-29 originated from studies exploring the link between snoRNAs and neurodevelopmental disorders. Scientists observed that mutations and deletions in the SNORD115-29 gene locus were associated with Prader-Willi syndrome (PWS) and Angelman syndrome (AS), two distinct neurogenetic disorders. This provided initial evidence suggesting that SNORD115-29 might play a crucial role in the pathogenesis of these conditions.

SNORD115-29 as a Disease Biomarker
One of the most significant challenges in diagnosing and monitoring diseases is the availability of reliable biomarkers. SNORD115-29 has shown promising potential as a disease biomarker due to its unique expression patterns and association with specific pathologies. Research studies have reported altered levels of SNORD115-29 in various conditions, including neurodevelopmental disorders, cancer, and cardiovascular diseases. These findings open new avenues for utilizing SNORD115-29 as a diagnostic tool in precision medicine.

Neurodevelopmental Disorders
PWS and AS are two neurodevelopmental disorders that share common genetic underpinnings but present distinct clinical features. Both conditions are associated with imprinted genes located within the SNORD115-29 gene cluster. Consequently, the dysregulation of SNORD115-29 expression contributes to the observed phenotypic abnormalities. Detecting and quantifying SNORD115-29 levels in patients can aid in the differential diagnosis and provide insights into disease progression.

Moreover, recent evidence suggests that SNORD115-29 may have implications beyond PWS and AS. Studies have highlighted its potential involvement in other neurodevelopmental disorders, such as autism spectrum disorder (ASD) and schizophrenia. Although further research is needed to elucidate precise mechanisms and establish reliable diagnostic criteria, SNORD115-29 holds promise as a biomarker for neurodevelopmental disorders.

The dysregulation of snoRNAs, including SNORD115-29, has been observed in various cancer types, suggesting their potential as oncogenic or tumor-suppressive factors. SNORD115-29 plays a significant role in modulating ribosomal RNA (rRNA) modification and maturation, affecting protein synthesis rates and contributing to cancer progression and metastasis.

Additionally, studies have reported altered SNORD115-29 expression associated with specific cancer subtypes. For instance, decreased SNORD115-29 expression levels have been observed in breast cancer, while increased expression has been linked to lung cancer. These findings highlight SNORD115-29 as a potential biomarker for cancer diagnosis, prognosis, and therapeutic targeting.

Cardiovascular Diseases
Emerging evidence suggests that SNORD115-29 may also play a role in cardiovascular diseases. Research studies have demonstrated altered expression of SNORD115-29 in patients with heart failure, atrial fibrillation, and myocardial infarction. SNORD115-29 may contribute to cardiac remodeling, fibrosis, and hypertrophy through its involvement in rRNA maturation and ribosome biogenesis, thus potentially serving as a biomarker for cardiovascular diseases.

Therapeutic Potential of SNORD115-29
The unique molecular characteristics of SNORD115-29 make it an attractive target for therapeutic intervention. As SNORD115-29 contributes to critical cellular processes, modulating its expression or function holds considerable promise for the development of novel disease treatments. However, the translation of this potential into clinical practice requires further research to elucidate the precise mechanisms of SNORD115-29 and establish effective intervention strategies.

In conclusion, SNORD115-29 represents a compelling biomarker candidate for various diseases, including neurodevelopmental disorders, cancer, and cardiovascular diseases. Its unique expression patterns and involvement in critical cellular processes make it a promising diagnostic tool and potential therapeutic target. Further research efforts should focus on unraveling the precise mechanisms underlying SNORD115-29 regulation and its implications in disease pathogenesis. Ultimately, SNORD115-29 holds great potential to revolutionize disease diagnosis, monitoring, and treatment, thereby improving patient outcomes in the future.

Protein Name: Small Nucleolar RNA, C/D Box 115-29

The "SNORD115-29 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD115-29 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

SNORD115-3 | SNORD115-30 | SNORD115-31 | SNORD115-32 | SNORD115-33 | SNORD115-36 | SNORD115-37 | SNORD115-38 | SNORD115-39 | SNORD115-4 | SNORD115-40 | SNORD115-41 | SNORD115-42 | SNORD115-43 | SNORD115-44 | SNORD115-48 | SNORD115-5 | SNORD115-6 | SNORD115-7 | SNORD115-8 | SNORD115-9 | SNORD116-1 | SNORD116-10 | SNORD116-11 | SNORD116-12 | SNORD116-13 | SNORD116-14 | SNORD116-15 | SNORD116-16 | SNORD116-17 | SNORD116-18 | SNORD116-19 | SNORD116-2 | SNORD116-20 | SNORD116-21 | SNORD116-22 | SNORD116-23 | SNORD116-24 | SNORD116-25 | SNORD116-26 | SNORD116-27 | SNORD116-28 | SNORD116-29 | SNORD116-3 | SNORD116-4 | SNORD116-5 | SNORD116-6 | SNORD116-7 | SNORD116-8 | SNORD116-9 | SNORD116@ | SNORD117 | SNORD118 | SNORD119 | SNORD11B | SNORD12 | SNORD121A | SNORD121B | SNORD123 | SNORD124 | SNORD125 | SNORD126 | SNORD12B | SNORD12C | SNORD13 | SNORD139 | SNORD13P2 | SNORD13P3 | SNORD14A | SNORD14B | SNORD14C | SNORD14D | SNORD14E | SNORD15A | SNORD15B | SNORD16 | SNORD17 | SNORD18A | SNORD18C | SNORD19 | SNORD19B | SNORD1A | SNORD1B | SNORD1C | SNORD2 | SNORD20 | SNORD21 | SNORD22 | SNORD23 | SNORD24 | SNORD25 | SNORD26 | SNORD27 | SNORD28 | SNORD29 | SNORD30 | SNORD31 | SNORD32A | SNORD32B | SNORD33